Company: LGNZZ
Filing Date: 2025-11-07
Form Type: 10-Q
Source: 0000886163-25-000063
Chunk: 5

Company: LIGAND PHARMACEUTICALS INC
Filing Date: 2025-11-07
Form: 10-Q
Item: Item 1
Chunk 5
---
2,560 Comprehensive income (loss)$118,101 $(4,491)$94,933 $29,619 

See accompanying notes to unaudited condensed consolidated financial statements.

6

LIGAND PHARMACEUTICALS INCORPORATED

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY 

(Unaudited)

(in thousands)

Common StockAdditional paid in capitalAccumulated other comprehensive income (loss)Retained earningsTotal stockholders’ equitySharesAmountBalance at December 31, 202419,106 $20 $337,377 $(5,942)$498,984 $830,439 ASU 2025-07 adoption: impact as of January 1, 2025 (Note 1)— — — — (438)(438)Issuance of common stock under employee stock compensation plans, net of shares withheld for payroll taxes170 — (4,669)— — (4,669)Share-based compensation— — 7,836 — — 7,836 Unrealized loss on available-for-sale securities, net of tax— — — (22)— (22)Foreign currency translation adjustment, net of tax— — — 4,401 — 4,401 Net loss (as reported)— — — — (42,451)(42,451)ASU 2025-07 adoption: impact on net loss— — — — 498 498 Balance at March 31, 2025*19,276 20 340,544 (1,563)456,593 795,594 Issuance of common stock under employee stock compensation plans, net of shares withheld for payroll taxes135 — 8,094 — — 8,094 Share-based compensation— — 9,997 — — 9,997 Unrealized loss on available-for-sale securities, net of tax— — — (49)— (49)Foreign currency translation adjustment, net of tax— — — 10,106 — 10,106 Net income (as reported)— — — — 4,847 4,847 ASU 2025-07 adoption: impact on net income— — — — (1,276